CR20220582A - Anticuerpos anti-dectina-2 - Google Patents

Anticuerpos anti-dectina-2

Info

Publication number
CR20220582A
CR20220582A CR20220582A CR20220582A CR20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A
Authority
CR
Costa Rica
Prior art keywords
methods
binding agents
dectin
inventive
nucleic acids
Prior art date
Application number
CR20220582A
Other languages
English (en)
Inventor
David Dornan
Shelley Erin Ackerman
Karla A Henning
Justin A Kenkel
Original Assignee
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolt Biotherapeutics Inc filed Critical Bolt Biotherapeutics Inc
Publication of CR20220582A publication Critical patent/CR20220582A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a los agentes de unión a la lectina de tipo C asociada a células dendríticas 2 (Dectin-2), a los ácidos nucleicos que comprenden los agentes de unión inventivos, a los vectores y a las células que comprenden los ácidos nucleicos inventivos, y a las composiciones de los mismos. La invención también se refiere a métodos para proporcionar los agentes de unión inventivos, métodos para tratar una enfermedad, trastorno o afección en un mamífero y métodos para estimular una célula presentadora de antígeno
CR20220582A 2020-05-01 2021-05-03 Anticuerpos anti-dectina-2 CR20220582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018952P 2020-05-01 2020-05-01
PCT/US2021/030466 WO2021222894A1 (en) 2020-05-01 2021-05-03 Anti-dectin-2 antibodies

Publications (1)

Publication Number Publication Date
CR20220582A true CR20220582A (es) 2023-01-09

Family

ID=76076494

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220582A CR20220582A (es) 2020-05-01 2021-05-03 Anticuerpos anti-dectina-2

Country Status (13)

Country Link
US (2) US11753474B2 (es)
EP (1) EP4142881A1 (es)
JP (1) JP2023524092A (es)
KR (1) KR20230005907A (es)
CN (1) CN115461122A (es)
AU (1) AU2021262828A1 (es)
BR (1) BR112022020639A2 (es)
CA (1) CA3175576A1 (es)
CL (1) CL2022003012A1 (es)
CR (1) CR20220582A (es)
IL (1) IL297782A (es)
MX (1) MX2022013616A (es)
WO (1) WO2021222894A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470424A4 (en) * 2016-06-08 2020-03-04 Shanghai Jiaotong University School of Medicine SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
EP1272526A4 (en) 2000-04-13 2004-10-13 Univ Rockefeller REINFORCING ANTIBODY-IMMUNE RESPONSE
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
EP2455100A3 (en) 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
NZ721364A (en) 2014-02-10 2023-04-28 Merck Patent Gmbh Targeted tgfβ inhibition
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
BR112017010110A2 (pt) 2014-11-21 2018-01-30 Bristol-Myers Squibb Company anticorpos contra cd73 e usos do mesmo
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2018029586A1 (en) 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3645043A4 (en) * 2017-06-28 2021-04-07 The Board of Trustees of the Leland Stanford Junior University PROCEDURES AND COMPOSITIONS FOR DECTIN-2 STIMULATION AND CANCER IMMUNOTHERAPY
WO2020206354A1 (en) 2019-04-05 2020-10-08 Dren Bio, Inc. Methods of depleting disease causing agents via antibody targeted phagocytosis
JP2023545057A (ja) 2020-10-07 2023-10-26 ドレン バイオ， インコーポレイテッド 抗デクチン－１抗体及びその使用方法

Also Published As

Publication number Publication date
IL297782A (en) 2022-12-01
KR20230005907A (ko) 2023-01-10
EP4142881A1 (en) 2023-03-08
CN115461122A (zh) 2022-12-09
WO2021222894A1 (en) 2021-11-04
MX2022013616A (es) 2022-11-16
US20230406939A1 (en) 2023-12-21
BR112022020639A2 (pt) 2022-11-29
CA3175576A1 (en) 2021-11-04
JP2023524092A (ja) 2023-06-08
US11753474B2 (en) 2023-09-12
US20220153849A1 (en) 2022-05-19
CL2022003012A1 (es) 2023-06-23
AU2021262828A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
MX2022013616A (es) Anticuerpos anti-dectina-2.
MX2022008925A (es) Anticuerpos anti-pd-l1.
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
MY194642A (en) Antibodies binding to cd3
CL2020001898A1 (es) Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
CL2020002387A1 (es) Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123)
BR112013014265A8 (pt) sequência de ácido nucleico isolada, receptor antígeno quimérico isolado, célula, vetor, e, métodos para estimular uma resposta imune mediada por célula t, para fornecer uma imunidade antitumoral em um mamífero, para tratar um mamífero tendo uma doença, distúrbio ou condição, para tratar um ser humano com uma doença, para gerar uma população persistente de célula t, e para expandir uma população de célula t
WO2019232477A3 (en) Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
WO2012044999A3 (en) Reversible protein multimers, methods for their production and use
WO2020227159A3 (en) Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
BR112022004995A2 (pt) Anticorpos biespecíficos contra ceacam5 e cd3
MX2019012606A (es) Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
MX2022000016A (es) Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
CR20220639A (es) Anticuerpos que se unen a cd3 y folr1
MX2022016544A (es) Agentes de union a lair-1 y metodos para su uso.
CR20220628A (es) Anticuerpos que se unen a cd3
MX2023008809A (es) ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
US20200140813A1 (en) T-cell expansion method and uses
CL2021000177A1 (es) Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360)
MX2023001851A (es) Neoantigenos ras y usos de los mismos.
MX2022016548A (es) Muteínas de il-10 y proteínas de fusión de las mismas.